Global in-market sales of TYSABRI increased by 23 percent, and we hit key milestones that are important for unlocking the value of TYSABRI. The label was changed in the EU to include the presence of anti-JC virus (JCV) antibodies as a factor that increases the risk of a serious, but infrequent side effect known as progressive multifocal leukoencephalopathy (PML), and then subsequently in the U.S. in 2012. This change can help physicians and people with MS have more confidence in their treatment decisions when considering TYSABRI. Additionally, an assay to detect anti-ÂJCV antibodies, STRATIFY JCV, was made broadly available.
FAMPYRA (prolonged-Ârelease fampridine tablets) — the first treatment that addresses the unmet need of walking improvement in adults with MS — launched outside the U.S., and RITUXAN continued to be a significant revenue stream.